Cardiff Oncology Temettü
Temettü kriter kontrolleri 0/6
Cardiff Oncology does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-1.5%
Geri Alım Getirisi
Toplam Hissedar Getirisi | -1.5% |
Gelecekteki Temettü Verimi | n/a |
Temettü Büyümesi | n/a |
Bir sonraki temettü ödeme tarihi | n/a |
Eski temettü tarihi | n/a |
Hisse başına temettü | n/a |
Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if CRDF's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if CRDF's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
Cardiff Oncology Piyasaya Karşı Temettü Getirisi |
---|
Segment | Temettü Verimi |
---|---|
Şirket (CRDF) | n/a |
Pazarın Alt %25'i (US) | 1.5% |
Pazarın En İyi %25'i (US) | 4.5% |
Sektör Ortalaması (Biotechs) | 2.2% |
Analist tahmini (CRDF) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate CRDF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate CRDF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate CRDF's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as CRDF has not reported any payouts.